Brief: Janux Therapeutics Announces Positive Interim Clinical Data From Phase 1A Dose Escalation For PSMA-TRACTr JANX007
17/07/2023 14:05
July 17 (Reuters) - Janux Therapeutics Inc JANX.O :
* JANUX THERAPEUTICS ANNOUNCES POSITIVE INTERIM CLINICAL
DATA FROM
PHASE 1A DOSE ESCALATION FOR PSMA-TRACTR JANX007 AND AN UPDATE
ON PIPELINE PROGRAMS
* JANUX THERAPEUTICS INC - MULTIPLE PATIENTS TREATED WITH
PSMA-TRACTR JANX007 HAVE ACHIEVED MEANINGFUL PSA DROPS COUPLED
WITH MANAGEABLE SAFETY AND CRS
* JANUX THERAPEUTICS INC - JANX007 PRELIMINARY DATA SHOWED
ENCOURAGING SAFETY RESULTS CONSISTENT WITH ON-TUMOR ACTIVITY
WITH NO DOSE-LIMITING TOXICITIES
* JANUX THERAPEUTICS INC - PK EXPOSURE DEMONSTRATED TRACTR
ACTIVATION WITH LACK OF TCE ACCUMULATION
Source text for Eikon: ID:nBw2xK8Z5a
Further company coverage: JANX.O
((reuters.briefs@thomsonreuters.com;))